XML 24 R2.htm IDEA: XBRL DOCUMENT v3.24.3Close
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Total revenue $ 2,465.8 $ 2,530.3 $ 7,221.2 $ 7,449.3 Close
Cost and expenses:        
Cost of sales, excluding amortization and impairment of acquired intangible assets 638.7 659.6 1,726.9 1,915.1
Research and development 542.7 736.3 1,509.5 1,891.1
Selling, general and administrative 588.4 788.2 1,723.7 1,941.2
Amortization and impairment of acquired intangible assets 130.3 60.9 295.5 164.0
Collaboration profit sharing/(loss reimbursement) 69.3 50.5 197.3 164.5
(Gain) loss on fair value remeasurement of contingent consideration 23.8 0.0 23.8 0.0
Restructuring charges 6.8 76.0 24.9 120.0
Gain on sale of priority review voucher, net 0.0 0.0 88.6 0.0
Other (income) expense, net 14.8 300.0 193.7 248.2
Total cost and expense 2,014.8 2,671.5 5,606.7 6,444.1 Close
Income (loss) before income tax (benefit) expense 451.0 (141.2) 1,614.5 1,005.2 Close
Income tax (benefit) expense 62.5 (72.9) 249.0 92.6 Close
Net income (loss) 388.5 (68.3) 1,365.5 912.6 Close
Net income (loss) attributable to noncontrolling interests, net of tax 0.0 (0.2) 0.0 1.2
Net income (loss) attributable to Biogen Inc. $ 388.5 $ (68.1) $ 1,365.5 $ 911.4
Net income per share:        
Basic earnings (loss) per share attributable to Biogen Inc. $ 2.67 $ (0.47) $ 9.38 $ 6.30
Diluted earnings (loss) per share attributable to Biogen Inc. $ 2.66 $ (0.47) $ 9.35 $ 6.26
Weighted-average shares used in calculating:        
Basic earnings (loss) per share attributable to Biogen Inc. 145,700 144,800 145,500 144,700
Diluted earnings (loss) per share attributable to Biogen Inc. 146,100 144,800 146,000 145,500
Product, net        
Total revenue $ 1,769.4 $ 1,805.2 $ 5,380.9 $ 5,414.3
Revenue from anti-CD20 therapeutic programs        
Total revenue 446.2 420.9 1,284.7 1,253.8
Contract manufacturing, royalty and other revenue        
Total revenue $ 250.2 $ 304.2 $ 555.6 $ 781.2